Clinicopathological analysis of expression of enhancer of zeste homologue 2 in canine mammary carcinoma

1Abdelmegeed S.M., Mohammed S.: Canine mammary tumors as a model for human disease. Oncol Lett 2018, 15, 8195–8205, doi.org/10.3892/ol.2018.8411. Abdelmegeed S.M. Mohammed S. Canine mammary tumors as a model for human disease Oncol Lett 2018 15 8195 8205 doi.org/10.3892/ol.2018.8411Open DOISearch in Google Scholar

2Bohrer L.R., Chen S., Hallstrom T.C., Huang H.: Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: A potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology 2010, 151, 5136–5145, doi.org/10.1210/en.2010-0436. Bohrer L.R. Chen S. Hallstrom T.C. Huang H. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: A potential mechanism of androgen-refractory progression of prostate cancer Endocrinology 2010 151 5136 5145 doi.org/10.1210/en.2010-0436Open DOISearch in Google Scholar

3Boros J., Arnoult N., Stroobant V., Collet J.F., Decottignies A.: Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1alpha at chromatin. Mol Cell Biol 2014, 34, 3662–3674, doi.org/10.1128/MCB.00205-14. Boros J. Arnoult N. Stroobant V. Collet J.F. Decottignies A. Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1alpha at chromatin Mol Cell Biol 2014 34 3662 3674 doi.org/10.1128/MCB.00205-14Open DOISearch in Google Scholar

4Canadas A., Franca M., Pereira C., Vilaca R., Vilhena H., Tinoco F., Silva M.J., Ribeiro J., Medeiros R., Oliveira P., Dias-Pereira P, Santos M.: Canine mammary tumors: Comparison of classification and grading methods in a survival study. Vet Pathol 2019, 56, 208–219, doi.org/10.1177/0300985818806968. Canadas A. Franca M. Pereira C. Vilaca R. Vilhena H. Tinoco F. Silva M.J. Ribeiro J. Medeiros R. Oliveira P. Dias-Pereira P Santos M. Canine mammary tumors: Comparison of classification and grading methods in a survival study Vet Pathol 2019 56 208 219 doi.org/10.1177/0300985818806968Open DOISearch in Google Scholar

5Cardoso C., Mignon C., Hetet G., Grandchamps B., Fontes M., Colleaux L.: The human EZH2 gene: Genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 2000, 8, 174–180, doi.org/10.1038/sj.ejhg.5200439. Cardoso C. Mignon C. Hetet G. Grandchamps B. Fontes M. Colleaux L. The human EZH2 gene: Genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders Eur J Hum Genet 2000 8 174 180 doi.org/10.1038/sj.ejhg.5200439Open DOISearch in Google Scholar

6Choi H.J., Lee H.B., Park H.K., Cho S.M., Han H.J., Lee S.J., Lee J.Y., Nam S.J., Cho E.H., Son W.C.: EZH2 expression in naturally occurring canine tumors. Comp Med 2018, 68, 148–155. Choi H.J. Lee H.B. Park H.K. Cho S.M. Han H.J. Lee S.J. Lee J.Y. Nam S.J. Cho E.H. Son W.C. EZH2 expression in naturally occurring canine tumors Comp Med 2018 68 148 155Search in Google Scholar

7Choi H.J., Jang S., Ryu J.E., Lee H.J., Lee H.B., Ahn W.S., Kim H.J., Lee H.J., Lee H.J., Gong G.Y, Son W.C.: Significance of EZH2 expression in canine mammary tumors. Bmc Vet Res 2016, 12, 164, doi.org/10.1186/s12917-016-0789-2. Choi H.J. Jang S. Ryu J.E. Lee H.J. Lee H.B. Ahn W.S. Kim H.J. Lee H.J. Lee H.J. Gong G.Y Son W.C. Significance of EZH2 expression in canine mammary tumors Bmc Vet Res 2016 12 164 doi.org/10.1186/s12917-016-0789-2Open DOISearch in Google Scholar

8Ding L, Kleer C.G.: Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 2006, 66, 9352-5, doi.org/10.1158/0008-5472.CAN-06-2384. Ding L Kleer C.G. Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast Cancer Res 2006 66 9352 5 doi.org/10.1158/0008-5472.CAN-06-2384Open DOISearch in Google Scholar

9Duan R., Du W., Guo W.: EZH2: A novel target for cancer treatment. J Hematol Oncol 2020, 13, 104, doi.org/10.1186/s13045-020-00937-8. Duan R. Du W. Guo W. EZH2: A novel target for cancer treatment J Hematol Oncol 2020 13 104 doi.org/10.1186/s13045-020-00937-8Open DOISearch in Google Scholar

10Eich M.L., Athar M., Ferguson J.R., Varambally S.: EZH2-Targeted Therapies in Cancer: Hype or a Reality. Cancer Res 2020, 80, 5449–5458, doi.org/10.1158/0008-5472.CAN-20-2147. Eich M.L. Athar M. Ferguson J.R. Varambally S. EZH2-Targeted Therapies in Cancer: Hype or a Reality Cancer Res 2020 80 5449 5458 doi.org/10.1158/0008-5472.CAN-20-2147Open DOISearch in Google Scholar

11Fan Y., Ren X., Liu X., Shi D., Xu E., Wang S., Liu Y.: Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients. Sci Rep 2021, 11, 6651, doi.org/10.1038/s41598-021-85029-4. Fan Y. Ren X. Liu X. Shi D. Xu E. Wang S. Liu Y. Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients Sci Rep 2021 11 6651 doi.org/10.1038/s41598-021-85029-4Open DOISearch in Google Scholar

12Gao B., Liu X., Li Z., Zhao L., Pan Y.: Overexpression of EZH2/NSD2 histone methyltransferase axis predicts poor prognosis and accelerates tumor progression in Triple-Negative breast cancer. Front Oncol 2020, 10, 600514, doi.org/10.3389/fonc.2020.600514. Gao B. Liu X. Li Z. Zhao L. Pan Y. Overexpression of EZH2/NSD2 histone methyltransferase axis predicts poor prognosis and accelerates tumor progression in Triple-Negative breast cancer Front Oncol 2020 10 600514 doi.org/10.3389/fonc.2020.600514Open DOISearch in Google Scholar

13Hobert O., Jallal B., Ullrich A.: Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Mol Cell Biol 1996, 16, 3066–3073, doi.org/10.1128/mcb.16.6.3066. Hobert O. Jallal B. Ullrich A. Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression Mol Cell Biol 1996 16 3066 3073 doi.org/10.1128/mcb.16.6.3066Open DOISearch in Google Scholar

14Inari H., Suganuma N., Kawachi K., Yoshida T., Yamanaka T., Nakamura Y., Yoshihara M., Nakayama H., Yamanaka A., Masudo K., Oshima T., Yokose T., Rino Y., Shimizu S., Miyagi Y., Masuda M.: Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions. Bmc Cancer 2017, 17, 160, doi.org/10.1186/s12885-017-3154-3. Inari H. Suganuma N. Kawachi K. Yoshida T. Yamanaka T. Nakamura Y. Yoshihara M. Nakayama H. Yamanaka A. Masudo K. Oshima T. Yokose T. Rino Y. Shimizu S. Miyagi Y. Masuda M. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions Bmc Cancer 2017 17 160 doi.org/10.1186/s12885-017-3154-3Open DOISearch in Google Scholar

15Jang S.H., Lee J.E., Oh M.H., Lee J.H., Cho H.D., Kim K.J., Kim S.Y., Han S.W., Kim H.J., Bae S.B., Lee H.J.: High EZH2 protein expression is associated with poor overall survival in patients with luminal a breast cancer. J Breast Cancer 2016, 19, 53–60, doi.org/10.4048/jbc.2016.19.1.53. Jang S.H. Lee J.E. Oh M.H. Lee J.H. Cho H.D. Kim K.J. Kim S.Y. Han S.W. Kim H.J. Bae S.B. Lee H.J. High EZH2 protein expression is associated with poor overall survival in patients with luminal a breast cancer J Breast Cancer 2016 19 53 60 doi.org/10.4048/jbc.2016.19.1.53Open DOISearch in Google Scholar

16Kaszak I., Ruszczak A., Kanafa S., Kacprzak K., Krol M., Jurka P.: Current biomarkers of canine mammary tumors. Acta Vet Scand 2018, 60, 66, doi.org/10.1186/s13028-018-0417-1. Kaszak I. Ruszczak A. Kanafa S. Kacprzak K. Krol M. Jurka P. Current biomarkers of canine mammary tumors Acta Vet Scand 2018 60 66 doi.org/10.1186/s13028-018-0417-1Open DOISearch in Google Scholar

17Lutful K.F., Alvarez C.E., Bird R.C.: Canine mammary carcinomas: A comparative analysis of altered gene expression. Vet Sci 2015, 3, doi.org/10.3390/vetsci3010001. Lutful K.F. Alvarez C.E. Bird R.C. Canine mammary carcinomas: A comparative analysis of altered gene expression Vet Sci 2015 3 doi.org/10.3390/vetsci3010001Open DOISearch in Google Scholar

18Margueron R., Reinberg D.: The Polycomb complex PRC2 and its mark in life. Nature 2011, 469, 343–349, doi.org/10.1038/nature09784. Margueron R. Reinberg D. The Polycomb complex PRC2 and its mark in life Nature 2011 469 343 349 doi.org/10.1038/nature09784Open DOISearch in Google Scholar

19Mohammad F., Weissmann S., Leblanc B., Pandey D.P., Hojfeldt J.W., Comet I., Zheng C., Johansen J.V., Rapin N., Porse B.T., Tvardovskiy A., Jensen ON., Olaciregui NG., Lavarino C., Sunol M., de Torres C., Mora J., Carcaboso A.M., Helin K.: EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 2017, 23, 483–492, doi.org/10.1038/nm.4293. Mohammad F. Weissmann S. Leblanc B. Pandey D.P. Hojfeldt J.W. Comet I. Zheng C. Johansen J.V. Rapin N. Porse B.T. Tvardovskiy A. Jensen ON. Olaciregui NG. Lavarino C. Sunol M. de Torres C. Mora J. Carcaboso A.M. Helin K. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas Nat Med 2017 23 483 492 doi.org/10.1038/nm.4293Open DOISearch in Google Scholar

20Qiu J., Sharma S., Rollins R.A., Paul T.A.: The complex role of EZH2 in the tumor microenvironment: Opportunities and challenges for immunotherapy combinations. Future Med Chem 2020, 12, 1415–1430, doi.org/10.4155/fmc-2020-0072. Qiu J. Sharma S. Rollins R.A. Paul T.A. The complex role of EZH2 in the tumor microenvironment: Opportunities and challenges for immunotherapy combinations Future Med Chem 2020 12 1415 1430 doi.org/10.4155/fmc-2020-0072Open DOISearch in Google Scholar

21Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H., Packeisen J., Sewalt RA., Otte A.P., van Diest P.J.: Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003, 5, 481–488, doi.org/10.1016/s1476-5586(03)80032-5. Raaphorst F.M. Meijer C.J. Fieret E. Blokzijl T. Mommers E. Buerger H. Packeisen J. Sewalt RA. Otte A.P. van Diest P.J. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene Neoplasia 2003 5 481 488 doi.org/10.1016/s1476-5586(03)80032-5Open DOISearch in Google Scholar

22Ramadan E.S., Salem N.Y., Emam I.A., Abdelkader N.A., Farghali H.A., Khattab M.S.: MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors. Vet Res Commun 2021, doi.org/10.1007/s11259-021-09861-9. Ramadan E.S. Salem N.Y. Emam I.A. Abdelkader N.A. Farghali H.A. Khattab M.S. MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors Vet Res Commun 2021 doi.org/10.1007/s11259-021-09861-9Open DOISearch in Google Scholar

23Roh J.W., Choi J.E., Han H.D., Hu W., Matsuo K., Nishimura M., Lee J.S., Kwon S.Y., Cho C.H., Kim J., Coleman R.L., Lopez-Bernstein G, Sood AK.: Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther 2020, 21, 147–156, doi.org/10.1080/15384047.2019.1672455. Roh J.W. Choi J.E. Han H.D. Hu W. Matsuo K. Nishimura M. Lee J.S. Kwon S.Y. Cho C.H. Kim J. Coleman R.L. Lopez-Bernstein G Sood AK. Clinical and biological significance of EZH2 expression in endometrial cancer Cancer Biol Ther 2020 21 147 156 doi.org/10.1080/15384047.2019.1672455Open DOISearch in Google Scholar

24Senhorello I., Terra E.M., Sueiro F., Firmo B.F., Anai L.A., Goloni C., Canavari I.C., Ampuero R., Pereira R.S, Tinucci-Costa M.: Clinical value of carcinoembryonic antigen in mammary neoplasms of bitches. Vet Comp Oncol 2020, 18, 315–323, doi.org/10.1111/vco.12552. Senhorello I. Terra E.M. Sueiro F. Firmo B.F. Anai L.A. Goloni C. Canavari I.C. Ampuero R. Pereira R.S Tinucci-Costa M. Clinical value of carcinoembryonic antigen in mammary neoplasms of bitches Vet Comp Oncol 2020 18 315 323 doi.org/10.1111/vco.12552Open DOISearch in Google Scholar

25Song X., Gao T., Wang N., Feng Q., You X., Ye T., Lei Q., Zhu Y., Xiong M., Xia Y., Yang F., Shi Y., Wei Y., Zhang L, Yu L.: Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Sci Rep 2016, 6, 20864, doi.org/10.1038/srep20864. Song X. Gao T. Wang N. Feng Q. You X. Ye T. Lei Q. Zhu Y. Xiong M. Xia Y. Yang F. Shi Y. Wei Y. Zhang L Yu L. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer Sci Rep 2016 6 20864 doi.org/10.1038/srep20864Open DOISearch in Google Scholar

26Tang X., Zhou T., Shen J., Luo M., Yuan H., Pan D, Li F.: The expression and potential mechanism of EGFR and EZH2 in breast cancer. Gland Surg 2021, 10, 2535–2545, doi.org/10.21037/gs-21-505. Tang X. Zhou T. Shen J. Luo M. Yuan H. Pan D Li F. The expression and potential mechanism of EGFR and EZH2 in breast cancer Gland Surg 2021 10 2535 2545 doi.org/10.21037/gs-21-505Open DOISearch in Google Scholar

27Valdivia G., Alonso-Diez A., Perez-Alenza D, Pena L.: From conventional to precision therapy in canine mammary cancer: A comprehensive review. Front Vet Sci 2021, 8, 623800, doi.org/10.3389/fvets.2021.623800. Valdivia G. Alonso-Diez A. Perez-Alenza D Pena L. From conventional to precision therapy in canine mammary cancer: A comprehensive review Front Vet Sci 2021 8 623800 doi.org/10.3389/fvets.2021.623800Open DOISearch in Google Scholar

28Valencakova-Agyagosova A., Frischova Z., Sevcikova Z., Hajurka J., Lepej J., Szakallova I., Kredatusova G., Nagy V., Ledecky V.: Determination of carcinoembryonic antigen and cancer antigen (CA 15-3) in bitches with tumours on mammary gland: Preliminary report. Vet Comp Oncol 2014, 12, 205–214, doi.org/10.1111/j.1476-5829.2012.00353.x. Valencakova-Agyagosova A. Frischova Z. Sevcikova Z. Hajurka J. Lepej J. Szakallova I. Kredatusova G. Nagy V. Ledecky V. Determination of carcinoembryonic antigen and cancer antigen (CA 15-3) in bitches with tumours on mammary gland: Preliminary report Vet Comp Oncol 2014 12 205 214 doi.org/10.1111/j.1476-5829.2012.00353.xOpen DOISearch in Google Scholar

29Vantaku V., Putluri V., Bader DA., Maity S., Ma J., Arnold J.M., Rajapakshe K., Donepudi S.R., von Rundstedt FC., Devarakonda V., Dubrulle J., Karanam B., Mcguire S.E., Stossi F., Jain A.K., Coarfa C., Cao Q., Sikora A.G., Villanueva H., Kavuri S.M., Lotan Y., Sreekumar A, Putluri N.: Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene 2020, 39, 6265– 6285, doi.org/10.1038/s41388-019-0902-7. Vantaku V. Putluri V. Bader DA. Maity S. Ma J. Arnold J.M. Rajapakshe K. Donepudi S.R. von Rundstedt FC. Devarakonda V. Dubrulle J. Karanam B. Mcguire S.E. Stossi F. Jain A.K. Coarfa C. Cao Q. Sikora A.G. Villanueva H. Kavuri S.M. Lotan Y. Sreekumar A Putluri N. Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression Oncogene 2020 39 6265–6285 doi.org/10.1038/s41388-019-0902-7Open DOISearch in Google Scholar

30Wang S., Cai L., Zhang F., Shang X., Xiao R, Zhou H.: Inhibition of EZH2 attenuates sorafenib resistance by targeting NOTCH1 Activation-Dependent liver cancer stem cells via NOTCH1-Related MicroRNAs in hepatocellular carcinoma. Transl Oncol 2020, 13, 100741, doi.org/10.1016/j.tranon.2020.01.002. Wang S. Cai L. Zhang F. Shang X. Xiao R Zhou H. Inhibition of EZH2 attenuates sorafenib resistance by targeting NOTCH1 Activation-Dependent liver cancer stem cells via NOTCH1-Related MicroRNAs in hepatocellular carcinoma Transl Oncol 2020 13 100741 doi.org/10.1016/j.tranon.2020.01.002Open DOISearch in Google Scholar

31Xu J., Wang Z., Lu W., Jiang H., Lu J., Qiu J, Ye G.: EZH2 promotes gastric cancer cells proliferation by repressing p21 expression. Pathol Res Pract 2019, 215, 152374, doi.org/10.1016/j.prp.2019.03.003. Xu J. Wang Z. Lu W. Jiang H. Lu J. Qiu J Ye G. EZH2 promotes gastric cancer cells proliferation by repressing p21 expression Pathol Res Pract 2019 215 152374 doi.org/10.1016/j.prp.2019.03.003Open DOISearch in Google Scholar